Phase 2 Head and Neck Cancer Trial, Recruiting NCT04191460 Sponsor: Erasmus Medical Center Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 2 Head and Neck Cancer Trial, Recruiting

NCT04191460
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the mouth, confirmed by a tissue biopsy, and whose cancer is suitable for surgical removal
  • People who are 18 years of age or older
  • People who have given written consent to participate before being enrolled in the trial
  • People whose heart tracing (ECG) and blood/urine test results are either within normal ranges, or if slightly outside normal ranges, are considered medically unimportant by the trial team

Who may not be able to join:

  • People who have previously had surgery, chemotherapy, or radiotherapy affecting the mouth or oral cavity
  • People who have a history of a serious allergic reaction or severe hypersensitivity to any ingredient in the trial treatment
  • People who are pregnant or breastfeeding, or people of childbearing or fathering potential who are not using effective contraception
  • People with significant kidney problems, specifically where kidney function is measured below a certain level (eGFR less than 60) (confirm with trial site)
  • People who have previously had a kidney transplant
  • People with a weakened or impaired immune system, whether due to an existing medical condition or medications they are taking
  • People with any other condition that the trial doctor believes could put the person's health at risk or affect the trial's goals

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 010 704 13 57

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Erasmus Medical Center
Registry
ClinicalTrials.gov
Start date
12 July 2022
Est. completion
1 May 2025

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

WP-I: (Highest) mean tumor-to-background ratio (TBR); WP-II: Rate of adequate (i.e. >5mm clear) tumor resection margins.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov